Global Blood-Based Biomarker Market Size is valued at USD 7.9 Bn in 2024 and is predicted to reach USD 15.9 Bn by the year 2034 at a 7.4% CAGR during the forecast period for 2025-2034.
A blood-based biomarker refers to a measurable and quantifiable characteristic in the blood that indicates a particular physiological or pathological process, or a response to a therapeutic intervention. Biomarkers are valuable tools in medicine and research as they can provide information about normal biological processes, the presence of disease, or the response to treatment.
Blood-based biomarkers can assist in quantifying health and disease by measuring an individual's biochemistry from a simple patient blood sample. Several factors influence the blood-based biomarker market, contributing to its growth and development. These drives are frequently related to technological developments, a better understanding of disease causes, and a demand for personalized and non-invasive diagnostic methods.
However, the COVID-19 pandemic has had a substantial influence on various industries, including the healthcare industry and diagnostic markets, and has had an impact on the blood-based biomarker business. The epidemic shifted research emphasis to better understanding and managing COVID-19. Resources and efforts that were previously devoted to other diseases and biomarker research may have been redirected, potentially affecting timetables for the creation of specific blood-based biomarkers.
The Blood-Based Biomarker Market is segmented based on type, disease, and application. Based on type, the market is segmented as Screening Biomarkers, Diagnosis Biomarkers, and Others. The disease segment includes Cancer, Neurological Disorders, and Others. The application segment is segmented into Diagnostics, Drug Discovery, and Personalized Medicine.
The Diagnosis Biomarker category is expected to hold a major share in the global Blood-Based Biomarker Market in 2022. Various factors that contribute to the development, use, and progress of biomarker-based diagnostic technologies drive the blood-based biomarker-based diagnosis market. These factors represent the increasing significance of blood-based biomarkers in personalized medicine, disease identification, and therapy monitoring. Technological advances in genomes, proteomics, and metabolomics enable identifying and validating new blood-based biomarkers. High-throughput sequencing, mass spectrometry, and other omics techniques aid in discovering disease-specific biomarkers.
The Cancer segment is projected to grow rapidly in the global Blood-Based Biomarker Market. Various factors contribute to the development, use, and progress of biomarker technologies for cancer diagnosis, prognosis, and therapy monitoring, which drive the blood-based biomarker for the cancer market. Ongoing advances in genomes, proteomics, and other omics technologies help identify new blood-based cancer biomarkers. High-throughput sequencing, mass spectrometry, and other modern approaches aid in discovering and confirming biomarkers.
The North American Blood Biomarker Market is expected to register the maximum market share in revenue in the near future. The expanding usage of such markers in personalized medicine and various commercial expansion tactics employed by market players, such as partnerships and collaborations with existing pharmaceutical and biotechnological businesses in this region, can be credited to the region's substantial share. The Asia Pacific region is witnessing an increase in the prevalence of cancer, which is linked to several reasons, such as ageing populations, altered lifestyles, and exposure to environmental variables. This raises the need for blood-based biomarkers to detect and track cancer.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 7.9 Bn |
| Revenue Forecast In 2034 | USD 15.9 Bn |
| Growth Rate CAGR | CAGR of 7.4% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, Disease, Application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Diadem srl, Proteomedix, Cleveland Diagnostics, F. Hoffmann-La Roche Ltd., GENFIT, Nutech Cancer Biomarkers India Pvt Ltd., SysmOex Corporation, Minomic, Creative Diagnostics, Eisai Co., Ltd., C2N Diagnostics and Others |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Blood-Based Biomarker Market By Type-
Blood-Based Biomarker Market By Disease-
Blood-Based Biomarker Market By Application-
Blood-Based Biomarker Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.